ABSTRACT OBJECTIVE : To observe the clinical efficacy and safety of moxifloxacin in the management of urinogenital infection and to conduct pharmacoeconomical analysis of this drug . METHODS : A total of 76 cases with urinogenital infections were enrolled ( of which , 22 were patients with cystitis , 16 were with pyelonephritis , 12 were with prostatitis , 5 were with epididymis , 15 were with gonococcal urethritis and 6 were with other urinary tract infections) : 38 ( treatment group , ratio of male to female : 26 vs . 12 , aged at 45 13) were assigned to receive Moxifloxacin tablets 400 mg peros q . d. for 7 days , another 38 ( control group , ratio of male to female : 25 vs . 13 , aged at 45 12)to receive Gatifloxacin 0. 2g iv gtt b. i. d. for 7 days . The 2 groups were observed with regard to clinical efficacy , bacteria clearance and adverse reactions ; meanwhile , a cost -minimization analysis was performed on the 2 groups . RESULTS : The total response rates , bacteria clearance rates and incidences of adverse reaction in treatment group vs . in control group were 86. 8 %( 33 38)vs . 89. 5% ( 34 38) , 91. 3% ( 42 46 )vs . 92. 0% ( 46 50) and 2. 63 % ( 1 38)vs . 5. 26 % ( 2 38 ) , respectively , showing no significance between the 2 groups ( P> 0. 05) , but the medical fee in treatment group was significantly lower than in control group B ( P< 0. 01) . CONCLUSION : For patients with urinogenital infection , oral administration of moxiloxacin is not only safe and effective , but also more economical and reasonable . KEY WORDS moxifloxacin ; urogenital infection ; gatifloxacin ; pharmacoeconomics ; cost minimization analysis
